News

Penumbra Inc (PEN) reports a 13.4% revenue increase, driven by US thrombectomy success, while navigating international ...
What Happened? Shares of medical device company Penumbra (NYSE:PEN) jumped 11.8% in the afternoon session after the company ...
Key Points Penumbra topped analyst forecasts with $339.5 million in GAAP revenue and $0.86 non-GAAP EPS, driven by double-digit U.S. thrombectomy growth. Gross margin (GAAP) expanded sharply to 66.0%, ...
In the preceding three months, 7 analysts have released ratings for Penumbra PEN, presenting a wide array of perspectives ...
Medical device company Penumbra (NYSE:PEN) announced in Q2 CY2025, with sales up 13.4% year on year to $339.5 million. The ...
Medical device company Penumbra (NYSE:PEN) will be reporting earnings this Tuesday after market hours. Here’s what you need ...
Explore Penumbra's Q2 2025 earnings highlights, featuring 13.4% growth, U.S. thrombectomy success, RUBY XL launch insights, and updated revenue guidance.
Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second ...
Penumbra’s U.S. thrombectomy business was the standout performer, with revenue jumping 22.6% YoY to $188.5 million. The company’s U.S. venous thromboembolism (VTE) revenue showed particularly strong ...
Penumbra's aspiration-based mechanical thrombectomy devices are building one of the most defensible competitive moats in ...
ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Penumbra Inc. (PEN) on Tuesday reported second-quarter earnings of $45.3 million. The Alameda, California-based company said it had net income of $1.15 ...